Shorter immune maintenance for stage IV lung cancer after initial treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study and be able to come for scheduled visits and lab tests.
- Your lung cancer must be stage IV NSCLC confirmed by tissue or (in some cases) cytology from a prepared sample.
- You must have measurable tumors on CT or MRI scans.
- Your immune therapy plan starts only after standard chemo-immunotherapy induction, and you should have had disease control after that.
- Your recent health status should be strong enough: ECOG 0–1, weight loss under 10% in 3 months, and expected survival over 3 months.
- You must have enough usable tumor tissue for testing, and it should not be from a previously radiated area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial compares two approaches after initial chemotherapy and immunotherapy for advanced non-small cell lung cancer: giving additional local treatment (like surgery or radiation) to remaining spots versus continuing immunotherapy. It aims to see which strategy better controls the cancer.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy before a shorter course of radiation helps older or less fit patients with stage III lung cancer. It aims to improve treatment results while being more manageable for patients who might not tolerate standard therapies.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Hear when a new Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.